Nobody should defend the status quo. Routine screening exists for only a handful of cancers.
FDA
The panel voted 8-6 despite agency scientists’ warnings that certain peptide chemicals lack evidence of safety or...
Patients with no other options are watching an agency turn on its own scientists — and the...
Bemotrizinol — already common in Mexico, Canada and South Korea — won FDA approval on June 9,...
